Ronald Herb­st fol­lows Med­Im­mune ex­o­dus to Pyx­is CSO post; Jeff God­dard to suc­ceed CEO of AIT Bio­science

→ The out­flow of top ex­ecs from Med­Im­mune con­tin­ues to fill the lead­er­ship ranks of small­er biotechs. The lat­est to take off is Ronald Herb­st, the head of on­col­o­gy re­search, who’s as­sum­ing the CSO post at Pyx­is On­col­o­gy.  

Herb­st was part of the old Med­Im­mune or­ga­ni­za­tion As­traZeneca CEO Pas­cal So­ri­ot re­struc­tured ear­li­er this year, re­or­ga­niz­ing the com­pa­ny and elim­i­nat­ing the sto­ried sub­sidiary as a sep­a­rate or­ga­ni­za­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER